Margetuximab-cmkb - Biologic Drug Details

Summary for margetuximab-cmkb

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for margetuximab-cmkb

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	HER2/neu Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for margetuximab-cmkb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for margetuximab-cmkb Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for margetuximab-cmkb Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Margetuximab-cmkb

Last updated: March 5, 2026

What is Margetuximab-cmkb?

Margetuximab-cmkb is a CD76 targeting monoclonal antibody developed by MacroGenics. It was designed to treat HER2-positive breast cancer, serving as an alternative to trastuzumab (Herceptin). The drug is an Fc-engineered antibody optimized to enhance immune cell recruitment by increasing affinity for activating Fc gamma receptors.

Regulatory and Clinical Status

• FDA Approval: February 2021 for HER2-positive metastatic breast cancer after prior treatment.
• Indications: Approved for adult patients with metastatic or unresectable HER2-positive breast cancer who have received at least two prior anti-HER2 regimens.
• Clinical Trials: The SOPHIA trial (Phase 3) demonstrated a progression-free survival (PFS) benefit over trastuzumab, extending median PFS from 5.8 to 4.9 months, but with no significant overall survival (OS) improvement.

Market Size and Opportunities

Segment	Estimated Market Size	Notes
Global HER2-positive breast cancer	$7.5 billion (2022)	Based on Global Data estimates; includes metastatic and early stages
Target patient population	200,000 annually	Approximate annual incidence in the U.S. and EU
Prevalence of prior treatments	150,000 eligible patients	Based on clinical guidelines requiring at least two prior regimens

Competitive Landscape

• Trastuzumab (Herceptin): Dominant with over 20 years on the market, annual sales exceeding $7 billion globally.
• Other HER2-targeted therapies:
  • Pertuzumab (Perjeta): Adds to trastuzumab for combination therapy.
  • T-DM1 (Kadcyla): Antibody-drug conjugate, with 2022 sales of approximately $2.2 billion.
  • Pyrotinib and Tucatinib: Small molecule inhibitors approved in China and the U.S. respectively.

Key Competitors	Market Share (2022)	Differentiation Focus
Trastuzumab	80%	Established efficacy and infrastructure
T-DM1	10%	Targeted delivery of cytotoxic agent
Novel agents	10%	Combination or next-generation therapeutics

Margetuximab-cmkb faces competition primarily from trastuzumab. The clinical benefit over trastuzumab (median PFS gain of 1 month) has not translated into significant OS improvement, limiting its differentiation.

Financial Trajectory and Revenue Outlook

• Initial sales: Expected limited due to existing HER2 therapies.
• Market penetration: Contingent on demonstrating clinical advantage and securing reimbursement.
• Pricing: Typically priced similar to trastuzumab biosimilars, $60,000–$70,000 annually per patient.
• Adoption barriers: Require clinician education, safety profile validation, and insurance coverage.

Year	Estimated Revenue (USD millions)	Assumptions
2023	60	Launch year, conservative uptake
2024	150	Increased adoption, payer coverage
2025	250	Market penetration improves

Based on hypothetical growth rates tied to clinical positioning and competitive dynamics, revenues could reach $250–$350 million annually by 2025 if the drug demonstrates incremental clinical benefits and gains clinician acceptance.

Pricing and Reimbursement Landscape

• Pricing trends: Biosimilar competition is likely to pressure prices downward.
• Reimbursement considerations: Payers demand clear evidence of improved outcomes, which remains a challenge.
• Off-label use: Little expected given targeted indication.

Regulatory and Market Risks

• Clinical efficacy: The modest PFS benefit may limit label expansion.
• Market competition: Biosimilars of trastuzumab launched globally, reducing pricing power.
• Coverage and reimbursement: Potential delays if real-world outcomes do not meet expectations.
• Pipeline developments: New agents or combinations may overshadow margetuximab's role.

Strategic Considerations

• Positioning: Focus on patient subgroups with immune markers favoring Fc-engineered antibody efficacy.
• Partnerships: Collaborate with payers to demonstrate cost-effectiveness.
• Clinical trials: Explore additional indications or combination therapies.
• Cost management: Minimize manufacturing costs to remain competitive in pricing.

Summary

Margetuximab-cmkb is positioned as a targeted therapy for specific HER2-positive breast cancer patients. Its clinical benefit over existing treatments is modest, limiting its appeal to a narrow subset and constraining revenue growth. Market penetration depends heavily on demonstrating clear outcome benefits, navigating biosimilar competition, and securing favorable reimbursement.

Key Takeaways

• Market size for HER2-positive metastatic breast cancer is approximately $7.5 billion annually.
• Margetuximab's clinical advantage over trastuzumab is limited to a modest PFS extension.
• Biosimilar competition for trastuzumab introduces pricing pressure.
• Revenue forecasts suggest a gradual increase to around $250 million by 2025, contingent on market acceptance.
• Long-term success hinges on positioning in niche patient populations and expanding indications.

FAQs

1. How does margetuximab compare to trastuzumab in clinical efficacy?
It shows a median PFS benefit of approximately 1 month over trastuzumab but no significant OS improvement.

2. What is the primary market challenge for margetuximab?
Demonstrating a meaningful clinical advantage over established therapies amid biosimilar competition.

3. Can margetuximab expand into other indications?
Potentially, if trials show efficacy in early breast cancer or other HER2-positive cancers.

4. What pricing strategies could influence its market uptake?
Competitive biosimilar pricing and value-based reimbursement negotiations.

5. What regulatory hurdles could restrict market growth?
Limited efficacy benefits and the emergence of more effective combinations or newer agents.

References

1. FDA. (2021). Margetuximab Summary of Safety and Probable Benefit.
2. MacroGenics. (2022). SOPHIA Trial Data.
3. Global Data Healthcare. (2022). HER2-positive Breast Cancer Market Analysis.
4. EvaluatePharma. (2022). Oncology Drug Sales Data.
5. BIOSIM Center. (2022). Biosimilar Competition Trends.